These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy. Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365 [TBL] [Abstract][Full Text] [Related]
4. C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab. Garg N; Zhang Y; Nicholson-Weller A; Khankin EV; Borsa NG; Meyer NC; McDermott S; Stillman IE; Rennke HG; Smith RJ; Pavlakis M Nephrol Dial Transplant; 2018 Dec; 33(12):2260-2265. PubMed ID: 29370420 [TBL] [Abstract][Full Text] [Related]
5. Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease. Tran CL; Sethi S; Murray D; Cramer CH; Sas DJ; Willrich M; Smith RJ; Fervenza FC Pediatr Nephrol; 2016 Apr; 31(4):683-7. PubMed ID: 26759144 [TBL] [Abstract][Full Text] [Related]
6. C3 glomerulopathy and eculizumab: a report on four paediatric cases. Lebreton C; Bacchetta J; Dijoud F; Bessenay L; Fremeaux-Bacchi V; Sellier-Leclerc AL Pediatr Nephrol; 2017 Jun; 32(6):1023-1028. PubMed ID: 28236143 [TBL] [Abstract][Full Text] [Related]
7. Pathology after eculizumab in dense deposit disease and C3 GN. Herlitz LC; Bomback AS; Markowitz GS; Stokes MB; Smith RN; Colvin RB; Appel GB; D'Agati VD J Am Soc Nephrol; 2012 Jul; 23(7):1229-37. PubMed ID: 22677550 [TBL] [Abstract][Full Text] [Related]
8. A case of C3 glomerulonephritis successfully treated with eculizumab. Payette A; Patey N; Dragon-Durey MA; Frémeaux-Bacchi V; Le Deist F; Lapeyraque AL Pediatr Nephrol; 2015 Jun; 30(6):1033-7. PubMed ID: 25796589 [TBL] [Abstract][Full Text] [Related]
9. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G; Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851 [TBL] [Abstract][Full Text] [Related]
10. Kidney Transplantation in C3 Glomerulopathy: A Case Series. Regunathan-Shenk R; Avasare RS; Ahn W; Canetta PA; Cohen DJ; Appel GB; Bomback AS Am J Kidney Dis; 2019 Mar; 73(3):316-323. PubMed ID: 30413277 [TBL] [Abstract][Full Text] [Related]
11. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601 [TBL] [Abstract][Full Text] [Related]
12. C3 glomerulonephritis with a severe crescentic phenotype. Ravindran A; Fervenza FC; Smith RJH; Sethi S Pediatr Nephrol; 2017 Sep; 32(9):1625-1633. PubMed ID: 28593446 [TBL] [Abstract][Full Text] [Related]